Anti-Obscurin Ig Domain 1 [5H10] Antibody
![Anti-Obscurin Immunoglobulin Domain 1 [5H10] Antibody](https://www.kerafast.com/MediaStorage/Product/Images/Large/3207_2001202001275932060.jpg "Anti-Obscurin Ig Domain 1 [5H10] Antibody (supernatant)")
This mouse monoclonal antibody was generated against a recombinant form of the first immunoglobulin domain of obscurin-A/obscurin-B, and recognizes the N-terminus of human, mouse, and rat Obscurin Immunoglobulin domain 1 (amino acids 1-100).
Discovered about a decade ago, obscurin (720/870 kDa) is a member of a family of giant proteins originally identified in striated muscles that are essential for normal muscle formation and function. Recent evidence has indicated that variants of obscurin (‘‘obscurins’’) are expressed in non-muscle tissues too, where they contribute to distinct cellular processes. Dysfunction or abrogation of obscurins has been implicated in the development of several pathological conditions, including cardiac hypertrophy and cancer.
From the laboratories of Aikaterini Kontrogianni-Konstantopoulos, PhD and Robert J. Bloch, PhD, University of Maryland, Baltimore.
Part of The Investigator's Annexe program.
This mouse monoclonal antibody was generated against a recombinant form of the first immunoglobulin domain of obscurin-A/obscurin-B, and recognizes the N-terminus of human, mouse, and rat Obscurin Immunoglobulin domain 1 (amino acids 1-100).
Discovered about a decade ago, obscurin (720/870 kDa) is a member of a family of giant proteins originally identified in striated muscles that are essential for normal muscle formation and function. Recent evidence has indicated that variants of obscurin (‘‘obscurins’’) are expressed in non-muscle tissues too, where they contribute to distinct cellular processes. Dysfunction or abrogation of obscurins has been implicated in the development of several pathological conditions, including cardiac hypertrophy and cancer.
From the laboratories of Aikaterini Kontrogianni-Konstantopoulos, PhD and Robert J. Bloch, PhD, University of Maryland, Baltimore.
Part of The Investigator's Annexe program.
| Catalog Number | Product | DataSheet | Size | AVAILABILITY | Price | Qty |
|---|
| Product Type: | Antibody |
| Antigen: | Obscurin Immunoglobulin domain 1 |
| Accession ID: | Q5VST9, AJ002535.1 |
| Molecular Weight: | 720-870 kDa |
| Isotype: | IgG2 |
| Clonality: | Monoclonal |
| Clone Name: | 5H10 |
| Reactivity: | Mouse, Rat, Human |
| Immunogen: | Recombinant protein containing the first immunoglobulin domain of obscurin-A/obscurin-B |
| Species Immunized: | Mouse |
| Epitope: | Obscurin Immunoglobulin domain 1 (aa1-100) |
| Buffer: | Cell culture supernatant |
| Tested Applications: | Immunoblotting/ immunofluorescence,1:20-1:30; |
| Storage: | 4C Short Term, -80C Long Term |
| Shipped: | Cold Packs |
- Kontrogianni-Konstantopoulos, A., Jones, E., van Rossum, D., and Bloch, R.J., "Obscurin is a Ligand for Small Ankyrin 1 in Skeletal Muscle" Mol. Biol. Cell 14, 1138-1148, 2003.
- Kontrogianni-Konstantopoulos, A. and Bloch, R.J., "Obscurin: a multitasking muscle giant", J. Muscle Res. Cell Motility, 26, 419-426, 2006.
- Kontrogianni-Konstantopoulos, A., Catino, D.H., Strong, J.C., Sutter, S., Borisov, A.B., Pumplin, D.W., Russell, M.W., and Bloch, R.J. "Obscurin Modulates the Assembly and Organization of both the Myofibril and the Sarcoplasmic Reticulum" FASEB J., 20, 2102-2111, 2006.
- Bowman, A.L., Kontrogianni-Konstantopoulos, A., Hirsch, H., Geisler, S., Gonzalez-Serratos, H., Russell, M.W. and Bloch, R.J., "Different obscurin isoforms localize to distinct sites at sarcomeres". FEBS Letters, 581, 1549-54, 2007.
- Kontrogianni-Konstantopoulos, A., Ackermann, M.A, Bowman, A.L., Yap, S.L. and Bloch, R.J., "Muscle giants: Molecular templates in sarcomerogenesis", Physiol. Reviews, 89 (4), 1217-1267, 2009.
- Perry, N.A., Ackermann, M.A., Shriver, M., Hu, L.Y., and Kontrogianni-Konstantopoulos A., Obscurins: Unassuming giants enter the spotlight, IUBMB Life, 65(6):479-86, 2013.
If you publish research with this product, please let us know so we can cite your paper.
